Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1810 results
September 2020
-
StatementAveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy
-
Featured NewsBold Advocates for Blood Cancers and Blood Disorders
Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.
-
Media ReleaseNew collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicinesThe collaboration aims to help alleviate supply and logistical constraints in the African Union member states Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division…
-
Key ReleaseNovartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% - bringing potential reach to over 23 million patients across…
August 2020
-
Guidance system lights a path for drug discovery
Novartis drug hunters leverage machine learning and automation to power a faster, smarter way to navigate to new drugs.
-
Media ReleaseNovartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiranPooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164…
-
Media ReleaseNovartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab Seven of ten patients discontinued eculizumab and remained on…
-
In The NewsSupply chain organization during the COVID-19 pandemicBalancing priorities of combating the crisis and ongoing trials.
-
Featured News50 Climate Leaders
At Novartis, we aim to be a leader in environmental sustainability and a catalyst for positive change both in our own operations and in our supply chain.
-
Media ReleaseNovartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia studyAt primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with…
-
In The NewsThe coronavirus is giving health and pharma companies a chance to woo tech talentNovartis Chief Digital Officer Bertrand Bodson says tech professionals don’t need a background in biology to switch industries.
-
Media ReleaseNovartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanomaPhase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported…
Pagination
- ‹ Previous page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- …
- 151
- › Next page